Emyria takes Australian psychedelic-care experience to FDA hearing

• Limited in-person speaking position at 14 September FDA hearing
• Australian experience spans clinical governance, therapist training, safety and data collection
• FDA discussion will cover training, access, patient safety and standardised evidence
• US expansion opportunities remain under assessment